Phase 2b/c trial in 121 adults with drug-susceptible pulmonary TB: 4-month delamanid, bedaquiline and quabodepistat gave end-of-treatment culture conversion in 96.0% vs 100.0% with 6-month RHEZ, meeting non-inferiority (−4.0%; 12% margin). Grade ≥3 AEs 11–20% vs 5%.
RCTn = 122
Dawson et al. Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial